Zhang Xiao, Tao Xiang-Chen, Zhang Jian, Li Zhi-Wei, Xu Yan-Yun, Wang Yu-Meng, Zhang Chun-Xiao, Mu Guo-Ying
Department of Ophthalmology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong 250000, China.
Zibo Eye Hospital, No. 33-6, Songlingxi Street, Zichuan, Zibo, Shandong 255100, China.
J Ophthalmol. 2015;2015:289467. doi: 10.1155/2015/289467. Epub 2015 Apr 2.
Riboflavin/UVA cross-linking is a technique introduced in the past decades for the treatment of keratoconus, keratectasia, and infectious keratitis. Its efficacy and safety have been investigated with clinical and laboratory studies since its first clinical application by Wollensak for the treatment of keratoconus. Although its complications are encountered during clinical practice, such as infection inducing risk, minimal invasion merits a further investigation on its future application in clinical practice. Recently, collagen cross-linking in sclera shows a promising prospect. In present study, we summarized the representative studies describing the clinical and laboratory application of collagen cross-linking published in past decades and provided our opinion on the positive and negative results of cross-linking in the treatment of ophthalmic disorders.
核黄素/紫外线A交联是过去几十年中引入的一种用于治疗圆锥角膜、角膜扩张和感染性角膜炎的技术。自Wollensak首次将其临床应用于圆锥角膜治疗以来，已通过临床和实验室研究对其疗效和安全性进行了调查。尽管在临床实践中会遇到其并发症，如感染诱发风险，但微创的优点值得进一步研究其在临床实践中的未来应用。最近，巩膜中的胶原交联显示出有前景的前景。在本研究中，我们总结了过去几十年发表的描述胶原交联临床和实验室应用的代表性研究，并对交联在眼科疾病治疗中的阳性和阴性结果发表了我们的看法。
